Effect of Flecainide on Longitudinal and Transverse Conduction Velocities in Ventricular Myocardium. An Experimental Study

Ángel Ferrero, Francisco J. Chorro, Joaquín Cánoves, Luis Mainar, Estrella Blasco, and Luis Such

BRIEF REPORTS

It is known that the effect of flecainide on longitudinal and transverse ventricular conduction velocities depends on the coupling interval. If this is so, whether the longitudinal or transverse direction is predominantly affected could depend on the magnitude of the coupling interval. In order to investigate this hypothesis, we studied the effect of flecainide, 1 \( \mu \text{mol/L} \), on conduction velocities in excised heart preparations from 11 rabbits using a basal cycle length of 250 ms and inserting 2 extrastimuli at a decreasing coupling interval.

Flecainide significantly reduced both conduction velocities. However, the effect increased as the coupling interval decreased for only the longitudinal velocity. At long coupling intervals, flecainide produced a greater reduction in transverse than longitudinal velocity, whereas, at short intervals, both velocities were affected similarly.

Key words: Flecainide. Conduction velocity. Ventricular myocardium.

INTRODUCTION

The effects of flecainide on myocardial tissue with its particular anisotropic structure have been the subject of various studies, including ones on its effect on longitudinal (LV) and transverse (TV) conduction velocities, and how the coupling interval influences this effect.\(^1\) However, the results have varied in that different authors have found that different effects predominate on LV and LV.\(^2\) The importance of studying the effects of flecainide on both velocities and the influence of the coupling interval on this effect is due to its possible relation to the proarrhythmic effects of the drug.\(^3\) If the effect of flecainide on longitudinal and transverse ventricular conduction velocities depends on the coupling interval, the predominance of the effects on the longitudinal direction compared to the transverse could depend on the coupling interval. Based on this hypothesis, our aim was to study the effects of flecainide on LV and TV with different coupling intervals in an isolated rabbit heart model, using high-resolution mapping techniques.

METHODS

The procedures followed in this study met the institutional standards and current guidelines for the care and use of laboratory animals.

Efectos de la flecainida sobre las velocidades de conducción longitudinal y transversal en el miocardio ventricular. Estudio experimental

Es conocido que el efecto de la flecainida sobre las velocidades de conducción ventricular longitudinal y transversal depende del acoplamiento entre estímulos. Si esto es así, el predominio de los efectos en sentido longitudinal frente al transversal puede variar en función de dicho acoplamiento. Con el objetivo de analizar dicha hipótesis, se ha estudiado el efecto de la flecainida (1 \( \mu \text{mol/l} \)) sobre dichas velocidades de conducción en 11 preparaciones de corazón aislado de conejo, para lo que se ha utilizado un tren base de estimulación de 250 ms y se han acoplado 2 extraestímulos con acoplamiento decreciente.

La flecainida ha reducido ambas velocidades de forma significativa. Este efecto se ha incrementado al reducir el acoplamiento únicamente en el caso de la velocidad longitudinal. Con acoplamientos largos, la flecainida ha producido una mayor reducción de la velocidad transversal que de la longitudinal, mientras que para intervalos cortos ha afectado en la misma proporción a ambas velocidades.

Eleven isolated Langendorff-perfused rabbit heart preparations (California breed) were studied. Epicardial ventricular electrograms were taken with a plaque-electrode made up of 121 unipolar electrodes located in the left ventricular free wall. Ventricular stimulation was done with bipolar electrodes through 2-ms rectangular pulses at an intensity double the diastolic threshold.

On a basic 12-beat train $S_0-S_0$ (baseline cycle length of 250 ms) 2 extrastimuli were introduced at a decreasing coupling interval ($S_1$, $S_2$). $S_1$ was coupled 10 ms above the minimum interval that produced ventricular capture, and the second extrastimulus ($S_2$) added by applying the same procedure. Once the baseline study was completed, this was repeated 15 min after starting continuous flecainide perfusion at 1 µmol/L, a concentration within the range known to yield its characteristic electrophysiological effects.

The LV and TV at $S_0$, $S_1$ and $S_2$ were measured and compared before and after flecainide administration by analyzing epicardial activation maps based on the local activation time for each electrode. To this end, the separation was divided between 2 electrodes selected by the difference between their activation times, in both longitudinal and transverse directions (Figure 1). To compare the effects of the drug on conduction velocities and the influence of the coupling interval, the percentage decrease in the different velocities induced by the drug was calculated.

Comparisons between pairs of data were done using nonparametric statistical tests for related variables (Wilcoxon). Decreases in conduction velocities are expressed as percentages. A $P$ value less than .05 was considered significant.

RESULTS

The LV and TV were measured before and after administering flecainide. The results are summarized in the Table.

Flecainide significantly decreased both LV and TV for all the coupling intervals studied (Figure 2). There was a trend at baseline for LV to progressively decrease with decreased coupling intervals, which was not seen for TV. After administering the drug, this trend reached statistical significance only for LV (Figure 2).

The percentage decrease in TV was greater than in LV only in the case of $S_0$ (Figure 3). That is, flecainide reduced TV to a greater extent than LV at the longest coupling interval (250 ms), whereas this capacity was lost as the coupling interval decreased, with both velocities being affected similarly.
DISCUSSION

Flecainide significantly decreased both conduction velocities for each coupling interval used, due to powerfully blocking the fast Na+ inflow current to cardiomyocyte. Most authors have reached the same conclusion when studying both healthy and pathological cardiac tissue. According to our results, the coupling interval influences the effects of flecainide on LV, which has been described by other authors in clinical and experimental studies. However, in line with our results, none of these authors has described this effect on TV. The coupling interval-dependent effect of flecainide has been associated with several mechanisms, such as the drug channel’s slow recovery kinetics or the longer 0-phase action potential duration with early extrastimuli (factors involving longer drug-channel activation time).

Flecainide has shown a greater effect on TV only with long coupling intervals (250 ms). Different working groups studying the effects of flecainide on both velocities have obtained disparate results. Some authors have found the drug has a greater effect on LV, others have found a greater effect on TV and yet others have found a similar effect on both. This disparity was probably influenced by the fact that the analysis of these effects should be related to the coupling interval used. The importance of studying the effects of flecainide on LV and TV is due to the fact that its proarrhythmic effect could be explained through its interaction with the anisotropic ventricular tissue. The greatest effect of the drug on TV with long coupling intervals and the influence of the coupling interval (that emerge from our study) could lead to the appearance of areas of functional block and reentrant arrhythmias.

Limitations

No control group was used in the present study to rule out any observer effects due to variations in the preparations. However, previous studies using the same type of experimental preparation have verified its stability in periods similar to those used in this work.

![Figure 2](image-url)

Flecainide LV/TV: 2.8 (0.4) 2.4 (0.6)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>$S_0$</th>
<th>$S_1$</th>
<th>$S_2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline LV, cm/s</td>
<td>70.2 (13.5)</td>
<td>68.4 (12.6)</td>
<td>60.3 (14.2)</td>
</tr>
<tr>
<td>Flecainide LV, cm/s</td>
<td>51.4 (7.0)‡</td>
<td>44.2 (5.5)‡,§</td>
<td>39.2 (8.7)‡,¶</td>
</tr>
<tr>
<td>Longitudinal PD, %</td>
<td>24.8 (4.5)</td>
<td>34.3 (3.0)</td>
<td>34.0 (4.3)</td>
</tr>
<tr>
<td>Baseline TV, cm/s</td>
<td>28.6 (8.5)</td>
<td>28.6 (11.8)</td>
<td>26.9 (10.3)</td>
</tr>
<tr>
<td>Flecainide TV, cm/s</td>
<td>16.7 (3.2)‡</td>
<td>16.2 (2.7)‡</td>
<td>16.6 (5.2)‡</td>
</tr>
<tr>
<td>Transverse PD, %</td>
<td>37.8 (5.4)‡</td>
<td>36.5 (6.5)</td>
<td>35.0 (4.9)</td>
</tr>
<tr>
<td>Baseline LV/TV</td>
<td>2.6 (0.6)</td>
<td>2.8 (0.4)</td>
<td>2.4 (0.7)</td>
</tr>
<tr>
<td>Flecainide LV/TV</td>
<td>3.1 (0.6)‡</td>
<td>2.8 (0.4)</td>
<td>2.4 (0.6)</td>
</tr>
</tbody>
</table>

*PD indicates percentage decrease; LV, longitudinal conduction velocity; TV, transverse conduction velocity.
‡P<.05.
§P<.01 (level of significance for baseline differences vs flecainide, and longitudinal vs transverse).
¶P<.05.
‖P<.01 (level of significance of differences in S1 and S2 vs S0).

![Figure 2](image-url)

**Figure 2.** The LV and TV are shown for each coupling interval studied ($S_0$, $S_1$, and $S_2$), at baseline and after flecainide. *P<.05. NS indicates not significant.
In conclusion, the effect of flecainide on ventricular conduction velocities depends on the coupling interval. The drug produced a greater reduction in LV with decreasing coupling intervals, which was not found in the case of TV. The predominance of its effects on the longitudinal or transverse direction also depend on the coupling interval such that the effect on TV is greater with longer coupling intervals, but is the same on both velocities with shorter coupling intervals.

REFERENCES